Cannabidiol capsules Phase 1 clinical trial published
Results from the Phase 1 Clinical Trial have been published. The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in an international, peer-reviewed medical journal, Clinical Pharmacology in Drug Development. This clinical trial was completed in March 2016, and demonstrated the safety and high performance of the oral capsule technology, including the effective delivery profile of cannabidiol (“CBD”) compound to trial subjects. The Phase 1 Clinical Trial also highlighted the favourable bioavailability of the capsules in comparison to Sativex – a market-leading, commercially available cannabinoid oral spray produced by GW Pharmaceuticals (LON: GWP) (NASDAQ: GWPH).